Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Kinase domain receptor inhibitors

Stamos, J., Sliwkowski, M. X., Eigenbrot, C. (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277(48), 46265-46272. [Pg.108]

Imatinib (STI571) is an inhibitor of the tyrosine kinase domain of the Bcr-Abl oncoprotein and prevents the phosphorylation of the kinase substrate by ATP. It is indicated for the treatment of chronic myelogenous leukemia (CML), a pluripotent hematopoietic stem cell disorder characterized by the t(9 22) Philadelphia chromosomal translocation. This translocation results in the Bcr-Abl fusion protein, the causative agent in CML, and is present in up to 95% of patients with this disease. This agent inhibits other activated receptor tyrosine kinases for platelet-derived growth factor receptor (PDGFR), stem cell factor (SCF), and c-kit. [Pg.1307]

See other pages where Kinase domain receptor inhibitors is mentioned: [Pg.87]    [Pg.120]    [Pg.95]    [Pg.570]    [Pg.611]    [Pg.1261]    [Pg.1262]    [Pg.149]    [Pg.6]    [Pg.117]    [Pg.329]    [Pg.122]    [Pg.245]    [Pg.247]    [Pg.55]    [Pg.29]    [Pg.1309]    [Pg.206]    [Pg.6]    [Pg.55]    [Pg.243]    [Pg.845]    [Pg.168]    [Pg.7]    [Pg.95]    [Pg.570]    [Pg.611]    [Pg.1261]    [Pg.1262]    [Pg.129]    [Pg.1126]    [Pg.113]    [Pg.204]    [Pg.534]    [Pg.105]    [Pg.101]    [Pg.133]    [Pg.1256]    [Pg.275]    [Pg.339]    [Pg.884]    [Pg.68]    [Pg.563]   
See also in sourсe #XX -- [ Pg.87 , Pg.88 ]



SEARCH



Kinase domain

Kinase domain receptor

Kinase inhibitors

Kinase, kinases inhibitors

Receptor inhibitors

Receptor kinases

© 2024 chempedia.info